Sort   by:  
 Page size 
Background: Plasmodium falciparum causes the majority of malaria mortality worldwide, and the disease occurs during the asexual red blood cell (RBC) stage of infection. In the absence of an effective and available vaccine, and with increasing drug resistance, asexual RBC stage parasites are an impor...
ORGANISM(S): Homo sapiens (Human) Plasmodium falciparum 
2021-11-15 | PXD027301 | Pride
Background: Plasmodium falciparum causes the majority of malaria mortality worldwide, and the disease occurs during the asexual red blood cell (RBC) stage of infection. In the absence of an effective and available vaccine, and with increasing drug resistance, asexual RBC stage parasites are an impor...
ORGANISM(S): Homo sapiens (Human) Plasmodium falciparum 
2021-08-06 | PXD027241 | Pride
Plasmodium falciparum causes the most lethal form of malaria. The frontline treatments for this severe disease are combination therapies based on semisynthetic peroxide antimalarials, known as artemisinins. There is growing resistance to artemisinins and new drugs with novel mechanisms of action are...
ORGANISM(S): Homo sapiens (Human) Plasmodium falciparum 
2022-02-17 | PXD027334 | Pride
Merozoite invasion of host red blood cells (RBCs) is essential for survival of the human malaria parasite Plasmodium falciparum. Proteins involved with RBC binding and invasion are secreted from dual-club shaped organelles at the apical tip of the merozoite called the rhoptries. Here we characterise...
ORGANISM(S): Homo sapiens (Human) Plasmodium falciparum 
2021-11-15 | PXD028937 | Pride
To combat the global burden of malaria, development of new drugs to replace or complement current therapies are urgently required. As drug resistance to existing treatments and clinical failures continue to rise, compounds targeting multiple life cycle stages and species need to be developed as a hi...
ORGANISM(S): Homo sapiens (Human) 
2024-05-06 | PXD046006 | Pride
The development of antimalarial drug resistance is an ongoing problem threatening progress towards malaria elimination, and antimalarial treatments are urgently needed for drug-resistant malaria infections. Host-directed therapies (HDT) represent an attractive strategy for the devel-opment of new an...
ORGANISM(S): Homo sapiens (Human) Plasmodium falciparum 365.1 
2022-05-19 | PXD032276 | Pride
Plasmodium falciparum, the causative agent of malaria, continues to remain a global health threat since these parasites are now resistant to all anti-malaria drugs used throughout the world. Accordingly, drugs with novel modes of action are desperately required to combat malaria. P. falciparum paras...
ORGANISM(S): Homo sapiens (Human) Plasmodium falciparum 365.1 
2022-09-12 | PXD032358 | Pride
Artemisinins are currently the first-line antimalarials, and rely on a peroxide pharmacophore for their potent activity. OZ277 (arterolane) and OZ439 (artefenomel) are newer synthetic peroxide-based antimalarials with potent activity against the deadliest malaria parasite, Plasmodium falciparum. Her...
ORGANISM(S): Homo sapiens (Human) Plasmodium falciparum (isolate 3D7) 
2020-05-25 | PXD014313 | Pride
The increasing incidence of antimalarial drug resistance to the first-line artemisinins, and their combination partner drugs, underpins an urgent need for new antimalarial drugs, ideally with a novel mechanism of action. The recently developed 2-aminomethylphenol, JPC-3210, (MMV 892646) is an erythr...
ORGANISM(S): Homo sapiens (Human) Plasmodium falciparum (isolate 3D7) 
2019-12-20 | PXD013539 | Pride
CD47 is a key innate immune checkpoint that inhibits phagocytosis by myeloid cells, contributing to immune evasion by cancer cells. Although CD47-blocking antibodies have shown promise in treating various malignancies, their efficacy in glioblastoma (GBM) remains limited, and the cell-intrinsic role...
ORGANISM(S): Homo sapiens (Human) 
2026-03-05 | PXD071366 | Pride
Sort   by:  
 Page size